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Speed Dating for Molecules
CombinatoRx Looks for That Special SynergyComing up with a novel drug can
make a company’s fortunes, but the
overall cost of screening for new
candidates is sizeable even before
clinical trials. Thus, companies
search for any possible shortcuts to
the process. Boston-based start-up
CombinatoRx (www.combinatorx.
com) promises faster and cheaper
drug discovery by conducting the
equivalent of speed dating for mole-
cules. The company screens paired
combinations of generic, pharmacol-
ogically active compounds in the
hope of stumbling upon desirable in-
teractions that can be turned into
therapies.
Curious Liquids
The former Curious Liquids cafe´ on
the corner of the Boston Common
was a grotto-like brick building that
looked like an apothecary shop. For
a group of young researchers in the
late summer of 1999, it was a splen-
did place to concoct a thoroughly
modern pharmaceutical venture. ‘‘I
got together with Mike Foley and
Alexis Borisy, and shortly thereafter
we brought Curtis Keith on board,’’
recalled Brent Stockwell, assistant
professor of biological sciences at
Columbia University, where he re-
searches signaling networks under-
lying disease phenotypes. ‘‘We were
looking to start a biotech company.
We realized that disease was a
multi-factorial process. But most of
the pharmaceutical industry, the bio-
technology industry, was focused
on finding single magic bullets that
could reverse a complex disease
phenotype. And to us it didn’t make
sense. We recognized that . when
clinicians treat cancer, for example,
a cocktail of four drugs is the stan-
dard type of regime that is used, or
with HIV therapy, a triple cocktail of
three drugs is the standard of care.’’
Stockwell and his colleagues de-
cided to screen combinations of ac-
tive small molecules to look for syn-
ergistic effects. ‘‘There are about
2000 drugs approved in the U.S.,’’said Stockwell. Choosing just pairs,
those 2000 compounds would give
2 million potential candidates.
Founded in March 2000, and
funded with $2.5 million in angel in-
vestments, CombinatoRx has since
raised a total of $180 million. This
includes $90 million in three rounds
from investors such as Boston Mil-
lennia Partners, Canaan Venture
Partners, and Flagship Ventures;
the $44.3 million raised in its IPO in
November, 2005; another $48 million
from a private placement in March,
2006; and revenue from partnership
agreements. As of April 2006, the




screens pairs of drugs,
bypassing the time-con-
suming synthesis stage
that marks the start of
most companies’ drug
discovery efforts.
A Little Agnosticism Goes
a Long Way
Using pre-approved compounds,
CombinatoRx screens pairs of
drugs, bypassing the time-consum-
ing synthesis stage that marks the
start of most companies’ drug dis-
covery efforts. As the company is
working with known drugs, they
can tap available data on toxicology,
dosing, and formulations. According
to Stockwell, the idea was to acquire
protectable intellectual property on
the combinations and quickly de-
velop them as drugs. ‘‘There is a
30- to 40-fold cost savings [over
novel molecule screening],’’ Stock-
well said, ‘‘Clinical trials will be dis-
ease-specific and will cost the
same or be even slightly more ex-
pensive.’’ By following this strategy,CombinatoRx hopes to reduce the
time it takes to bring a drug from dis-
covery to clinical trials.
After CombinatoRx researchers
identify a promising match, they
then determine the optimal concen-
tration ratio for the two compounds.
A dose response matrix is used to
quantify the combination effect be-
tween each pair in which the concen-
tration of each drug is varied and the
corresponding biological activity is
monitored. The results of the binary
combinations are then analyzed, in
the hope that the efficacy of the
sum will exceed that of the parts.
CombinatoRx draws inspiration
from systems biology. Instead of an-
alyzing individual components or
aspects of an organism, systems bi-
ologists focus on the overall system.
‘‘We believe that biology and, more-
over, diseases, are complicated,
poorly understood, and that, in
most cases, a single agent targeting
an individual molecular target is
probably not going to be sufficient
to address, and certainly not to
cure, a particular disease,’’ said
Grant Zimmermann, Ph.D, director
of Screening and Technology Devel-
opment at CombinatoRx. ‘‘The idea
is that we are looking for unantici-
pated effects. We are looking for
novel combinations of approved
drugs. We are trying to be very ag-
nostic. We just look at the data.’’
Unlikely Bedfellows
CombinatoRx’s matchmaking pro-
duces some odd couplings. For in-
stance, CRx-026, the company’s
Phase I cancer candidate, is a com-
bination of chlorpromazine, an anti-
psychotic drug, and pentamidine,
an anti-parasitic drug. While osten-
sibly this combo could help you re-
main calm and parasite-free, Com-
binatoRx hopes it will cure you of
cancer. By choosing such an un-
likely pair of compounds, the com-
pany hopes to strengthen their claim
on the end product intellectual prop-
erty. ‘‘The vast majority of drugs are
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462generic,’’ said Alexis Borisy, Combi-
natoRx president and CEO. ‘‘So if
you find a surprising, novel, non-ob-
vious combination between a pair,
something that you never could
have predicted a priori, by that defi-
nition of it being novel and non-obvi-
ous, it is a patentable invention .
The trump patent is the composition
of matter of that combination re-
gardless of its use.’’
CombinatoRx is hoping to gradu-
ate from pairs to trios, but since
2000 compounds would produce
over 1.3 trillion triplets to be com-
bined and further screened for opti-
mal concentration, the screening
and data analysis could be too
time-consuming for a company of
their size. Moreover, while Combi-
natoRx’s methodology is applicable
to novel molecules, the likely conse-
quence of delving into unapproved
compounds is the loss of their pre-
clinical cost advantage.
Their basic approach still has
risks. While the company is attempt-
ing to set up robust intellectual
property barriers, they acknowledge
in their 2006 10K annual report that
doctors can simply prescribe two
generic drugs in tandem instead of
their drugs. As for the question of
why physicians won’t do just that,
‘‘The formulation, the aligned re-
lease products that we create,
does not exist on the market place,
so there is nothing there for them
substitute the products for,’’ said
Borisy. ‘‘The PK/PD [pharmacoki-
netic-pharmacodynamic profile] is
highly relevant.’’
Then there is the regulatory risk:
while CombinatoRx can bypass pre-
clinical testing with its known com-
pounds, the specter of synergistic
side effects might spook the FDA,
and the agency might ask for further
clinical testing based on the drugs’
combined pharmaceutical effects.
The agency could also require tests
because the drugs used are essen-
tially being applied off-label or for
long-term, rather than acute, treat-
ment. ‘‘A lot of compounds go
through this preclinical testing. to
make sure they are ‘clean,’ meaning
they don’t significantly interact with
those enzymes or receptors associ-
ated with hazardous health condi-
tions, even though they might not
have anything to do with the activity
they are looking for, so these same
tests could discover a negative syn-ergistic effect,’’ said Peter Hodder,
associate professor of biochemistry
at Scripps Institute in Florida. ‘‘They
can know with reasonable assurance
that they are not hitting the most clin-
ically known things. Of course, you
can’t test absolutely every organ or
system with a particular drug, but
that is what clinical trials are for.’’
Molecular Mixology Gains
Momentum
Despite the potential risks, other
companies and research ventures
are eager to try the combinations
approach. In 2006, CombinatoRx
signed a $250,000 collaboration with
Fovea Pharmaceuticals, SA, for can-
didates to treat eye disease, worth
$20 million in potential milestone
payments. In 2005, the company
cut a $42 million multi-year deal with
Angiotech Pharmaceuticals for $27
million upfront and a $15 million pur-
chase of CombinatoRx stock, as well
as the possibility of additional mil-
lions in milestone payments, and li-
censed CRx-026 to HenKan Phar-
maceutical Company of Taiwan for
$500,000 upfront and potentially $23
million in milestone payments. The
company also conducted $500,000
in screening work for Novartis.
In a bid to make Singapore a bio-
tech hub, the country’s government
is disbursing economic development
money to lure biotech companies to
set up shop there. In August 2005,
CombinatoRx launched a subsidiary,
CombinatoRx Singapore, inconjunc-
tion with Bio*One Capital, to screen
for combinations of compounds to
treat infectious diseases such as
hepatitis, with an initial $2.5 million
grant from Singapore’s Biomedical
Sciences Investment Fund Pte, Ltd.
and potentially an additional $17.5
million in milestone payments.
CombinatoRx has also been col-
laborating with neurodegenerative
disease foundations such as CHDI,
which focuses on Huntington’s Dis-
ease, the Spinal Muscular Atrophy
Foundation (SMA Foundation), and
Accelerate Brain Cure (ABC2), which
is looking for brain cancer therapies.
Additionally, the company received
a $4.4 million grant in 2005 from
the National Institute of Allergy and
Infectious Diseases for anthrax toxin
research.
Everything but the Kitchen Sink
CombinatoRx currently has six can-
didates in clinical studies and othersin the preclinical pipeline for the
treatment of immunoinflammatory
diseases and other ailments, includ-
ing four selective steroid amplifiers,
CRx-139, CRx-102, CRx-119 and
CRx-170, in Phase II. The company’s
clinical stage synergistic cytokine
modulator, CRx-150, combines an
antidepressant and a cardiac drug.
CombinatoRx also has early stage
metabolic candidates.
In April, the company announced
encouraging results for CRx-170,
its oral asthma drug in Phase II trials,
which combines budesonide, a ste-
roid, with nortriptyline, which am-
plifies the steroid’s effectiveness at
treating lung inflammation, so less
can be used, reducing side effects.
‘‘We reported spectacular results
with CRX-102 [an anti-inflammatory
arthritis drug],’’ said Borisy. How-
ever, one anti-inflammatory, CRx-
119, did not meet its primary end-
point biomarker for periodontal dis-
ease, although the company is still
testing it for other disease indica-
tions, and CRx-140 for psoriasis
was discontinued.
According to Borisy’s cheery as-
sessments, the company has a
50% rate of success of advancing
candidates to Phase II trials, which
is above the industry success rate
of 20%–30% for Phase II data. ‘‘So
even if we were only at 25%, we
would still be enormously success-
ful because our cost going from the
start of a screen to that Phase II
data is $10 million or less fully
loaded, where the industry average,
[according to the Tufts DiMasi Study]
without capital weighting adjust-
ing cost and taking the lower number
is $150 million,’’ Borisy elaborated,
‘‘I would make the strong form of
the claim that some time in the fu-
ture, whether it is fifty years or a hun-
dred years from now, sooner or later,
that most new drugs will in fact be
combinations, will be multi-targeted
in nature, whether with a single mol-
ecule or cocktails of molecules. That
is the big picture idea behind Combi-
natoRx. Our approach of the empiri-
cal dumb screening today to find
these pairs that no one would have
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